Business · 10/06/1999
FDA Releases Draft Guidance for Levothyroxine Sodium Tablets
The FDA has released a draft guidance document outlining recommendations for in vivo pharmacokinetics and bioavailability studies and in vitro dissolution testing for levothyroxine sodium tablets, with written comments due by August 9, 1999.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →